Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Other Operating Expenses (2016 - 2025)

Corcept Therapeutics' Other Operating Expenses history spans 10 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 13.9% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $13.0 million, up 19.24%, while the annual FY2025 figure was $13.0 million, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $2.5 million at Corcept Therapeutics, down from $4.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $4.6 million in Q3 2025 and bottomed at $1.2 million in Q1 2022.
  • The 5-year median for Other Operating Expenses is $1.6 million (2023), against an average of $2.1 million.
  • The largest annual shift saw Other Operating Expenses tumbled 32.48% in 2021 before it surged 82.9% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $1.4 million in 2021, then rose by 9.31% to $1.5 million in 2022, then increased by 26.82% to $1.9 million in 2023, then soared by 57.49% to $3.0 million in 2024, then dropped by 13.9% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Other Operating Expenses are $2.5 million (Q4 2025), $4.6 million (Q3 2025), and $3.4 million (Q2 2025).